Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type-Reference-Cited by-同舟云学术

Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type

Published:2018-09-19 Issue:12 Volume:17 Page:2767-2779
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Wang Yemin,Chen Shary Yuting,Colborne Shane,Lambert Galen,Shin Chae Young,Santos Nancy Dos,Orlando Krystal A.,Lang Jessica D.,Hendricks William P.D.,Bally Marcel B.,Karnezis Anthony N.,Hass Ralf,Underhill T. Michael,Morin Gregg B.,Trent Jeffrey M.,Weissman Bernard E.,Huntsman David G.

Funder

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes;Cancers;2024-09-03

2. Deciphering the interplay of histone post-translational modifications in cancer: Co-targeting histone modulators for precision therapy;Life Sciences;2024-06

3. Immunotherapy combined with targeted therapy in advanced small cell carcinoma of the ovary of hypercalcemic type: A case of overall survival lasting for over 5 years;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-06

4. Small‐cell neuroendocrine carcinoma of the female genital tract: A comprehensive overview;Journal of Neuroendocrinology;2024-04-16

5. Acetate ameliorates ovarian mitochondrial dysfunction in letrozole-induced polycystic ovarian syndrome rat model by improving mitofusin-2;The Journal of Physiological Sciences;2024-04-01